TY - JOUR AU - Jemal, A. AU - Center, M. M. AU - DeSantis, C. AU - Ward, E. M. PY - 2010 DA - 2010// TI - Global patterns of cancer incidence and mortality rates and trends JO - Cancer Epidemiol Biomarkers Prev VL - 19 ID - Jemal2010 ER - TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin. VL - 65 ID - Torre2015 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin. VL - 65 ID - Siegel2015 ER - TY - STD TI - Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975_2011/. [Last accessed 7/28/2015.] UR - http://seer.cancer.gov/csr/1975_2011/ ID - ref4 ER - TY - JOUR AU - Hammond, M. E. AU - Hayes, D. F. AU - Dowsett, M. AU - Allred, D. C. AU - Hagerty, K. L. AU - Badve, S. PY - 2010 DA - 2010// TI - American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer JO - J Clin Oncol. VL - 28 ID - Hammond2010 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. AU - Hicks, D. G. AU - Dowsett, M. AU - McShane, L. M. AU - Allison, K. H. PY - 2013 DA - 2013// TI - American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update JO - J Clin Oncol VL - 31 ID - Wolff2013 ER - TY - JOUR AU - Sparano, J. A. AU - Fazzari, M. AU - Kenny, P. A. PY - 2010 DA - 2010// TI - Clinical application of gene expression profiling in breast cancer JO - Surg Oncol Clin N Am. VL - 19 ID - Sparano2010 ER - TY - JOUR AU - Sotiriou, C. AU - Pusztai, L. PY - 2009 DA - 2009// TI - Gene-expression signatures in breast cancer JO - N Engl J Med. VL - 360 ID - Sotiriou2009 ER - TY - JOUR AU - Cotlar, A. M. AU - Dubose, J. J. AU - Rose, D. M. PY - 2003 DA - 2003// TI - History of surgery for breast cancer: radical to the sublime JO - Curr Surg. VL - 60 ID - Cotlar2003 ER - TY - JOUR AU - Fisher, B. AU - Jeong, J. H. AU - Anderson, S. AU - Bryant, J. AU - Fisher, E. R. AU - Wolmark, N. PY - 2002 DA - 2002// TI - Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation JO - N Engl J Med. VL - 347 ID - Fisher2002 ER - TY - JOUR AU - Fisher, B. AU - Anderson, S. AU - Bryant, J. AU - Margolese, R. G. AU - Deutsch, M. AU - Fisher, E. R. PY - 2002 DA - 2002// TI - Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer JO - N Engl J Med. VL - 347 ID - Fisher2002 ER - TY - JOUR PY - 1988 DA - 1988// TI - Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women JO - N Engl J Med VL - 319 ID - ref12 ER - TY - JOUR PY - 2001 DA - 2001// TI - Tamoxifen for early breast cancer JO - Cochrane Database Syst Rev VL - 1 ID - ref13 ER - TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet VL - 365 ID - ref14 ER - TY - JOUR AU - Davies, C. AU - Godwin, J. AU - Gray, R. AU - Clarke, M. AU - Cutter, D. PY - 2011 DA - 2011// TI - Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials JO - Lancet VL - 378 ID - Davies2011 ER - TY - JOUR AU - Peto, R. AU - Davies, C. AU - Godwin, J. AU - Gray, R. AU - Pan, H. C. PY - 2012 DA - 2012// TI - Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials JO - Lancet VL - 379 ID - Peto2012 ER - TY - JOUR AU - Sorlie, T. AU - Tibshirani, R. AU - Parker, J. AU - Hastie, T. AU - Marron, J. S. AU - Nobel, A. PY - 2003 DA - 2003// TI - Repeated observation of breast tumor subtypes in independent gene expression data sets JO - Proc Natl Acad Sci U S A. VL - 100 ID - Sorlie2003 ER - TY - JOUR AU - Bastien, R. R. AU - Rodríguez-Lescure, Á. AU - Ebbert, M. T. AU - Prat, A. AU - Munárriz, B. AU - Rowe, L. PY - 2012 DA - 2012// TI - PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers JO - BMC Med Genomics. VL - 5 ID - Bastien2012 ER - TY - JOUR AU - Parker, J. S. AU - Mullins, M. AU - Cheang, M. C. AU - Leung, S. AU - Voduc, D. AU - Vickery, T. PY - 2009 DA - 2009// TI - Supervised risk predictor of breast cancer based on intrinsic subtypes JO - J Clin Oncol. VL - 27 ID - Parker2009 ER - TY - JOUR AU - Fisher, B. AU - Ravdin, R. G. AU - Ausman, R. K. AU - Slack, N. H. AU - Moore, G. E. AU - Noer, R. J. PY - 1968 DA - 1968// TI - Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation JO - Ann Surg. VL - 168 ID - Fisher1968 ER - TY - JOUR AU - Fisher, B. AU - Carbone, P. AU - Economou, S. G. AU - Frelick, R. AU - Glass, A. AU - Lerner, H. PY - 1975 DA - 1975// TI - 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings JO - N Engl J Med VL - 292 ID - Fisher1975 ER - TY - JOUR AU - Bonadonna, G. AU - Brusamolino, E. AU - Valagussa, P. AU - Rossi, A. AU - Brugnatelli, L. AU - Brambilla, C. PY - 1976 DA - 1976// TI - Combination chemotherapy as an adjuvant treatment in operable breast cancer JO - N Engl J Med. VL - 294 ID - Bonadonna1976 ER - TY - JOUR AU - Albain, K. S. AU - Barlow, W. E. AU - Ravdin, P. M. AU - Farrar, W. B. AU - Burton, G. V. AU - Ketchel, S. J. PY - 2009 DA - 2009// TI - Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial JO - Lancet VL - 374 ID - Albain2009 ER - TY - JOUR AU - Mansour, E. G. AU - Gray, R. AU - Shatila, A. H. AU - Osborne, C. K. AU - Tormey, D. C. AU - Gilchrist, K. W. PY - 1989 DA - 1989// TI - Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study JO - N Engl J Med VL - 320 ID - Mansour1989 ER - TY - JOUR AU - Mansour, E. G. AU - Gray, R. AU - Shatila, A. H. AU - Tormey, D. C. AU - Cooper, M. R. AU - Osborne, C. K. PY - 1998 DA - 1998// TI - Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study JO - J Clin Oncol. VL - 16 ID - Mansour1998 ER - TY - JOUR AU - Fisher, B. AU - Dignam, J. AU - Wolmark, N. AU - DeCillis, A. AU - Emir, B. AU - Wickerham, D. L. PY - 1997 DA - 1997// TI - Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer JO - J Natl Cancer Inst. VL - 89 ID - Fisher1997 ER - TY - JOUR AU - Abrams, J. S. PY - 2001 DA - 2001// TI - Adjuvant therapy for breast cancer--results from the USA consensus conference JO - Breast Cancer. VL - 8 ID - Abrams2001 ER - TY - JOUR AU - Munoz, D. AU - Near, A. M. AU - Ravesteyn, N. T. AU - Lee, S. J. AU - Schechter, C. B. AU - Alagoz, O. PY - 2014 DA - 2014// TI - Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality JO - J Natl Cancer Inst. VL - 106 ID - Munoz2014 ER - TY - JOUR AU - Paik, S. AU - Tang, G. AU - Shak, S. AU - Kim, C. AU - Baker, J. AU - Kim, W. PY - 2006 DA - 2006// TI - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer JO - J Clin Oncol. VL - 24 ID - Paik2006 ER - TY - JOUR AU - Albain, K. S. AU - Barlow, W. E. AU - Shak, S. AU - Hortobagyi, G. N. AU - Livingston, R. B. AU - Yeh, I. T. PY - 2010 DA - 2010// TI - Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial JO - Lancet Oncol VL - 11 ID - Albain2010 ER - TY - JOUR AU - Harris, L. AU - Fritsche, H. AU - Mennel, R. AU - Norton, L. AU - Ravdin, P. AU - Taube, S. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer JO - J Clin Oncol VL - 25 ID - Harris2007 ER - TY - STD TI - Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer, Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;1:257–61. ID - ref32 ER - TY - JOUR AU - Baum, M. AU - Brinkley, D. M. AU - Dossett, J. A. AU - McPherson, K. AU - Patterson, J. S. AU - Rubens, R. D. PY - 1983 DA - 1983// TI - Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer JO - Lancet. VL - 2 ID - Baum1983 ER - TY - JOUR AU - Howell, A. AU - Cuzick, J. AU - Baum, M. AU - Buzdar, A. AU - Dowsett, M. AU - Forbes, J. F. PY - 2005 DA - 2005// TI - ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer JO - Lancet VL - 365 ID - Howell2005 ER - TY - JOUR AU - Thürlimann, B. AU - Keshaviah, A. AU - Coates, A. S. AU - Mouridsen, H. AU - Mauriac, L. PY - 2005 DA - 2005// TI - A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer JO - N Engl J Med VL - 353 ID - Thürlimann2005 ER - TY - JOUR AU - Goss, P. E. AU - Ingle, J. N. AU - Martino, S. AU - Robert, N. J. AU - Muss, H. B. AU - Piccart, M. J. PY - 2003 DA - 2003// TI - A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer JO - N Engl J Med. VL - 349 ID - Goss2003 ER - TY - JOUR AU - Davies, C. AU - Pan, H. AU - Godwin, J. AU - Gray, R. AU - Arriagada, R. AU - Raina, V. PY - 2013 DA - 2013// TI - Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial JO - Lancet VL - 381 ID - Davies2013 ER - TY - JOUR AU - Pagani, O. AU - Regan, M. M. AU - Walley, B. A. AU - Fleming, G. F. AU - Colleoni, M. AU - Láng, I. PY - 2014 DA - 2014// TI - International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer JO - N Engl J Med VL - 371 ID - Pagani2014 ER - TY - JOUR AU - Pagani, O. AU - Regan, M. M. AU - Francis, P. A. PY - 2014 DA - 2014// TI - Exemestane with ovarian suppression in premenopausal breast cancer JO - N Engl J Med VL - 371 ID - Pagani2014 ER - TY - JOUR AU - Romond, E. H. AU - Perez, E. A. AU - Bryant, J. AU - Suman, V. J. AU - Geyer, C. E. AU - Davidson, N. E. PY - 2005 DA - 2005// TI - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer JO - N Engl J Med. VL - 353 ID - Romond2005 ER - TY - JOUR AU - Joensuu, H. AU - Kellokumpu-Lehtinen, P. L. AU - Bono, P. AU - Alanko, T. AU - Kataja, V. AU - Asola, R. PY - 2006 DA - 2006// TI - FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer JO - N Engl J Med VL - 354 ID - Joensuu2006 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Procter, M. AU - Leyland-Jones, B. AU - Goldhirsch, A. AU - Untch, M. AU - Smith, I. PY - 2005 DA - 2005// TI - Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer JO - N Engl J Med VL - 353 ID - Piccart-Gebhart2005 ER - TY - JOUR AU - Slamon, D. AU - Eiermann, W. AU - Robert, N. AU - Pienkowski, T. AU - Martin, M. AU - Press, M. PY - 2011 DA - 2011// TI - Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer JO - N Engl J Med VL - 365 ID - Slamon2011 ER - TY - JOUR AU - Tolaney, S. M. AU - Barry, W. T. AU - Dang, C. T. AU - Yardley, D. A. AU - Moy, B. AU - Marcom, P. K. PY - 2015 DA - 2015// TI - Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer JO - N Engl J Med. VL - 372 ID - Tolaney2015 ER - TY - JOUR AU - Jones, S. E. AU - Collea, R. AU - Paul, D. AU - Sedlacek, S. AU - Favret, A. M. AU - Gore, I. PY - 2013 DA - 2013// TI - Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study JO - Lancet Oncol. VL - 14 ID - Jones2013 ER - TY - JOUR AU - Pivot, X. AU - Romieu, G. AU - Debled, M. AU - Pierga, J. Y. AU - Kerbrat, P. AU - Bachelot, T. PY - 2013 DA - 2013// TI - PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial JO - Lancet Oncol VL - 14 ID - Pivot2013 ER - TY - JOUR AU - Goldhirsch, A. AU - Gelber, R. D. AU - Piccart-Gebhart, M. J. AU - Azambuja, E. AU - Procter, M. AU - Suter, T. M. PY - 2013 DA - 2013// TI - Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial JO - Lancet VL - 382 ID - Goldhirsch2013 ER - TY - JOUR AU - Hutchinson, L. PY - 2013 DA - 2013// TI - Breast cancer: ALTTO: wake-up call for setting up clinical trials JO - Nat Rev Clin Oncol. VL - 10 ID - Hutchinson2013 ER - TY - JOUR AU - Loprinzi, C. L. AU - Ravdin, P. M. PY - 2003 DA - 2003// TI - Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians JO - J Natl Compr Canc Netw. VL - 1 ID - Loprinzi2003 ER - TY - JOUR AU - Olivotto, I. A. AU - Bajdik, C. D. AU - Ravdin, P. M. AU - Speers, C. H. AU - Coldman, A. J. AU - Norris, B. D. PY - 2005 DA - 2005// TI - Population-based validation of the prognostic model ADJUVANT! for early breast cancer JO - J Clin Oncol. VL - 23 ID - Olivotto2005 ER - TY - JOUR AU - Mook, S. AU - Schmidt, M. K. AU - Rutgers, E. J. AU - Velde, A. O. AU - Visser, O. AU - Rutgers, S. M. PY - 2009 DA - 2009// TI - Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study JO - Lancet Oncol. VL - 10 ID - Mook2009 ER - TY - JOUR AU - Hortobagyi, G. N. PY - 1997 DA - 1997// TI - Anthracyclines in the treatment of cancer JO - An overview. Drugs. VL - 54 ID - Hortobagyi1997 ER - TY - JOUR AU - Shockman, G. AU - Waksman, S. A. PY - 1951 DA - 1951// TI - Rhodomycin – an antibiotic produced by a red-pigmented mutant of Streptomyces griseus JO - Antibiot Chemother (Northfield) VL - 1 ID - Shockman1951 ER - TY - JOUR AU - Tan, C. AU - Etcubanas, E. AU - Wollner, N. AU - Rosen, G. AU - Gilladoga, A. AU - Showel, J. PY - 1973 DA - 1973// TI - Adriamycin – an antitumor antibiotic in the treatment of neoplastic diseases JO - Cancer. VL - 32 ID - Tan1973 ER - TY - JOUR AU - Brambilla, C. AU - Valagussa, P. AU - Bonadonna, G. PY - 1978 DA - 1978// TI - Sequential combination chemotherapy in advanced breast cancer JO - Cancer Chemother Pharmacol. VL - 1 ID - Brambilla1978 ER - TY - JOUR AU - Sparano, J. A. PY - 1998 DA - 1998// TI - Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations JO - Semin Oncol. VL - 25 ID - Sparano1998 ER - TY - JOUR AU - Torti, F. M. AU - Bristow, M. M. AU - Lum, B. L. AU - Carter, S. K. AU - Howes, A. E. AU - Aston, D. A. PY - 1986 DA - 1986// TI - Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy JO - Cancer Res. VL - 46 ID - Torti1986 ER - TY - JOUR AU - Ambrosini, G. AU - Balli, M. AU - Garusi, G. AU - Demicheli, R. AU - Jirillo, A. PY - 1988 DA - 1988// TI - Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial JO - J Clin Oncol VL - 6 ID - Ambrosini1988 ER - TY - JOUR AU - Wani, M. C. AU - Taylor, H. L. AU - Wall, M. E. AU - Coggon, P. AU - McPhail, A. T. PY - 1971 DA - 1971// TI - Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia JO - J Am Chem Soc VL - 93 ID - Wani1971 ER - TY - JOUR AU - Schiff, P. B. AU - Fant, J. AU - Horwitz, S. B. PY - 1979 DA - 1979// TI - Promotion of microtubule assembly in vitro by taxol JO - Nature. VL - 277 ID - Schiff1979 ER - TY - JOUR AU - Horwitz, S. B. PY - 2004 DA - 2004// TI - Personal recollections on the early development of taxol JO - J Nat Prod. VL - 67 ID - Horwitz2004 ER - TY - JOUR AU - Zasadil, L. M. AU - Andersen, K. A. AU - Yeum, D. AU - Rocque, G. B. AU - Wilke, L. G. AU - Tevaarwerk, A. J. PY - 2014 DA - 2014// TI - Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles JO - Sci Transl Med VL - 6 ID - Zasadil2014 ER - TY - JOUR AU - Weaver, B. A. PY - 2014 DA - 2014// TI - How taxol/paclitaxel kills cancer cells JO - Mol Biol Cell. VL - 25 ID - Weaver2014 ER - TY - JOUR AU - Rowinsky, E. K. AU - Donehower, R. C. PY - 1995 DA - 1995// TI - Paclitaxel (taxol) JO - N Engl J Med. VL - 332 ID - Rowinsky1995 ER - TY - JOUR AU - Ringel, I. AU - Horwitz, S. B. PY - 1991 DA - 1991// TI - Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol JO - J Natl Cancer Inst. VL - 83 ID - Ringel1991 ER - TY - JOUR AU - Schrijvers, D. AU - Wanders, J. AU - Dirix, L. AU - Prove, A. AU - Vonck, I. AU - Oosterom, A. PY - 1993 DA - 1993// TI - Coping with toxicities of docetaxel (Taxotere) JO - Ann Oncol. VL - 4 ID - Schrijvers1993 ER - TY - JOUR AU - Jones, S. E. AU - Erban, J. AU - Overmoyer, B. AU - Budd, G. T. AU - Hutchins, L. AU - Lower, E. PY - 2005 DA - 2005// TI - Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer JO - J Clin Oncol. VL - 23 ID - Jones2005 ER - TY - JOUR AU - Sledge, G. W. AU - Neuberg, D. AU - Bernardo, P. AU - Ingle, J. N. AU - Martino, S. AU - Rowinsky, E. K. PY - 2003 DA - 2003// TI - Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) JO - J Clin Oncol. VL - 21 ID - Sledge2003 ER - TY - JOUR AU - Bachegowda, L. S. AU - Makower, D. F. AU - Sparano, J. A. PY - 2014 DA - 2014// TI - Taxanes: impact on breast cancer therapy JO - Anticancer Drugs. VL - 25 ID - Bachegowda2014 ER - TY - JOUR AU - Tancini, G. AU - Bonadonna, G. AU - Valagussa, P. AU - Marchini, S. AU - Veronesi, U. PY - 1983 DA - 1983// TI - Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles JO - J Clin Oncol. VL - 1 ID - Tancini1983 ER - TY - JOUR AU - Bonadonna, G. AU - Moliterni, A. AU - Zambetti, M. AU - Daidone, M. G. AU - Pilotti, S. AU - Gianni, L. PY - 2005 DA - 2005// TI - 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study JO - BMJ. VL - 330 ID - Bonadonna2005 ER - TY - JOUR AU - Fisher, B. AU - Redmond, C. AU - Wickerham, D. L. AU - Bowman, D. AU - Schipper, H. AU - Wolmark, N. PY - 1989 DA - 1989// TI - Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience JO - J Clin Oncol. VL - 7 ID - Fisher1989 ER - TY - JOUR AU - Fisher, B. AU - Brown, A. M. AU - Dimitrov, N. V. AU - Poisson, R. AU - Redmond, C. AU - Margolese, R. G. PY - 1990 DA - 1990// TI - Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 JO - J Clin Oncol. VL - 8 ID - Fisher1990 ER - TY - JOUR AU - Fisher, B. AU - Anderson, S. AU - Tan-Chiu, E. AU - Wolmark, N. AU - Wickerham, D. L. AU - Fisher, E. R. PY - 2001 DA - 2001// TI - Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23 JO - J Clin Oncol. VL - 19 ID - Fisher2001 ER - TY - JOUR AU - Shulman, L. N. AU - Berry, D. A. AU - Cirrincione, C. T. AU - Becker, H. P. AU - Perez, E. A. AU - O'Regan, R. PY - 2014 DA - 2014// TI - Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance) JO - J Clin Oncol. VL - 32 ID - Shulman2014 ER - TY - JOUR AU - Namer, M. AU - Fargeot, P. AU - Roché, H. AU - Campone, M. AU - Kerbrat, P. AU - Romestaing, P. PY - 2006 DA - 2006// TI - French Adjuvant Study Group. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials JO - Ann Oncol VL - 17 ID - Namer2006 ER - TY - JOUR PY - 1988 DA - 1988// TI - A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin JO - J Clin Oncol VL - 6 ID - ref77 ER - TY - JOUR PY - 2001 DA - 2001// TI - Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial JO - J Clin Oncol VL - 19 ID - ref78 ER - TY - JOUR AU - Sparano, J. A. PY - 1999 DA - 1999// TI - Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics JO - Semin Oncol. VL - 26 ID - Sparano1999 ER - TY - JOUR AU - Norton, L. PY - 2001 DA - 2001// TI - Theoretical concepts and the emerging role of taxanes in adjuvant therapy JO - Oncologist VL - 6 ID - Norton2001 ER - TY - JOUR AU - Simon, R. AU - Norton, L. PY - 2006 DA - 2006// TI - The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens JO - Nat Clin Pract Oncol. VL - 3 ID - Simon2006 ER - TY - JOUR AU - Henderson, I. C. AU - Berry, D. A. AU - Demetri, G. D. AU - Cirrincione, C. T. AU - Goldstein, L. J. AU - Martino, S. PY - 2003 DA - 2003// TI - Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer JO - J Clin Oncol. VL - 21 ID - Henderson2003 ER - TY - JOUR AU - Mamounas, E. P. AU - Bryant, J. AU - Lembersky, B. AU - Fehrenbacher, L. AU - Sedlacek, S. M. AU - Fisher, B. PY - 2005 DA - 2005// TI - Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 JO - J Clin Oncol. VL - 23 ID - Mamounas2005 ER - TY - JOUR AU - Poole, C. J. AU - Earl, H. M. AU - Hiller, L. AU - Dunn, J. A. AU - Bathers, S. AU - Grieve, R. J. PY - 2006 DA - 2006// TI - NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer JO - N Engl J Med VL - 355 ID - Poole2006 ER - TY - JOUR AU - Jones, S. AU - Holmes, F. A. AU - O'Shaughnessy, J. AU - Blum, J. L. AU - Vukelja, S. J. AU - McIntyre, K. J. PY - 2009 DA - 2009// TI - Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 JO - J Clin Oncol. VL - 27 ID - Jones2009 ER - TY - JOUR AU - Nabholtz, J. M. AU - Mackey, J. R. AU - Smylie, M. AU - Paterson, A. AU - Noël, D. R. AU - Al-Tweigeri, T. PY - 2001 DA - 2001// TI - Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer JO - J Clin Oncol. VL - 19 ID - Nabholtz2001 ER - TY - JOUR AU - Nabholtz, J. M. AU - Falkson, C. AU - Campos, D. AU - Szanto, J. AU - Martin, M. AU - Chan, S. PY - 2003 DA - 2003// TI - Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial JO - J Clin Oncol. VL - 21 ID - Nabholtz2003 ER - TY - JOUR AU - Sparano, J. A. AU - O'Neill, A. AU - Schaefer, P. L. AU - Falkson, C. I. AU - Wood, W. C. PY - 2000 DA - 2000// TI - Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196 JO - J Clin Oncol. VL - 18 ID - Sparano2000 ER - TY - JOUR AU - Martin, M. AU - Pienkowski, T. AU - Mackey, J. AU - Pawlicki, M. AU - Guastalla, J. P. AU - Weaver, C. PY - 2005 DA - 2005// TI - Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer JO - N Engl J Med VL - 352 ID - Martin2005 ER - TY - JOUR AU - Nabholtz JM, P. T. AU - Mackey, J. AU - Pienkowski, T. AU - Pawlicki, M. AU - Guastalla, J. P. AU - Vogel, C. PY - 2002 DA - 2002// TI - Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study JO - Proc Am Soc Clin Oncol VL - 21 ID - Nabholtz JM2002 ER - TY - JOUR AU - Martin, M. AU - Seguí, M. A. AU - Antón, A. AU - Ruiz, A. AU - Ramos, M. AU - Adrover, E. PY - 2010 DA - 2010// TI - GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer JO - N Engl J Med VL - 363 ID - Martin2010 ER - TY - JOUR AU - Roche, H. AU - Fumoleau, P. AU - Spielmann, M. AU - Canon, J. L. AU - Delozier, T. AU - Serin, D. PY - 2006 DA - 2006// TI - Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial JO - J Clin Oncol. VL - 24 ID - Roche2006 ER - TY - JOUR AU - Coudert, B. AU - Asselain, B. AU - Campone, M. AU - Spielmann, M. AU - Machiels, J. P. AU - Pénault-Llorca, F. PY - 2012 DA - 2012// TI - UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial JO - Oncologist VL - 17 ID - Coudert2012 ER - TY - JOUR AU - Ellis, P. AU - Barrett-Lee, P. AU - Johnson, L. AU - Cameron, D. AU - Wardley, A. AU - O'Reilly, S. PY - 2009 DA - 2009// TI - TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial JO - Lancet VL - 373 ID - Ellis2009 ER - TY - JOUR AU - Martin, M. AU - Rodríguez-Lescure, A. AU - Ruiz, A. AU - Alba, E. AU - Calvo, L. AU - Ruiz-Borrego, M. PY - 2008 DA - 2008// TI - GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer JO - J Natl Cancer Inst VL - 100 ID - Martin2008 ER - TY - JOUR AU - Skipper, H. E. PY - 1986 DA - 1986// TI - Laboratory models: some historical perspective JO - Cancer Treat Rep. VL - 70 ID - Skipper1986 ER - TY - JOUR AU - Citron, M. L. AU - Berry, D. A. AU - Cirrincione, C. AU - Hudis, C. AU - Winer, E. P. AU - Gradishar, W. J. PY - 2003 DA - 2003// TI - Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 JO - J Clin Oncol. VL - 21 ID - Citron2003 ER - TY - BOOK AU - Hudis, C. AU - Citron, M. AU - Berry, D. AU - Cirrincione, C. AU - Gradishar, W. AU - Davidson, N. PY - 2005 DA - 2005// TI - Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective PB - San Antonio Breast Cancer Symposium CY - San Antonio, TX ID - Hudis2005 ER - TY - JOUR AU - Bonilla, L. AU - Ben-Aharon, I. AU - Vidal, L. AU - Gafter-Gvili, A. AU - Leibovici, L. AU - Stemmer, S. M. PY - 2010 DA - 2010// TI - Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials JO - J Natl Cancer Inst. VL - 102 ID - Bonilla2010 ER - TY - JOUR AU - Sparano, J. A. AU - Wang, M. AU - Martino, S. AU - Jones, V. AU - Perez, E. A. AU - Saphner, T. PY - 2008 DA - 2008// TI - Weekly paclitaxel in the adjuvant treatment of breast cancer JO - N Engl J Med. VL - 358 ID - Sparano2008 ER - TY - BOOK AU - Sparano, J. A. AU - Zhao, F. AU - Martino, S. AU - Ligibel, J. AU - Saphner, T. AU - Wolff, A. C. PY - 2014 DA - 2014// TI - Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer PB - San Antonio Breast Cancer Symposium CY - San Antonio, TX ID - Sparano2014 ER - TY - JOUR AU - Budd, G. T. AU - Barlow, W. E. AU - Moore, H. C. AU - Hobday, T. J. AU - Stewart, J. A. AU - Isaacs, C. PY - 2015 DA - 2015// TI - SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer JO - J Clin Oncol. VL - 33 ID - Budd2015 ER - TY - JOUR AU - Swain, S. M. AU - Jeong, J. H. AU - Geyer, C. E. AU - Costantino, J. P. AU - Pajon, E. R. AU - Fehrenbacher, L. PY - 2010 DA - 2010// TI - Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer JO - N Engl J Med. VL - 362 ID - Swain2010 ER - TY - JOUR AU - Sparano, J. A. AU - Solin, L. J. PY - 2010 DA - 2010// TI - Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making JO - J Clin Oncol. VL - 28 ID - Sparano2010 ER - TY - JOUR AU - Sparano, J. A. AU - Paik, S. PY - 2008 DA - 2008// TI - Development of the 21-gene assay and its application in clinical practice and clinical trials JO - J Clin Oncol. VL - 26 ID - Sparano2008 ER - TY - JOUR AU - Cardoso, F. AU - Piccart-Gebhart, M. AU - Veer, L. AU - Rutgers, E. PY - 2007 DA - 2007// TI - The MINDACT trial: the first prospective clinical validation of a genomic tool JO - Mol Oncol. VL - 1 ID - Cardoso2007 ER - TY - STD TI - National Comprehensive Cancer Network. www.nccn.org. [Last accessed 7/28/2015}] UR - http://www.nccn.org/ ID - ref107 ER - TY - JOUR AU - Swain, S. M. AU - Kim, S. B. AU - Cortés, J. AU - Ro, J. AU - Semiglazov, V. AU - Campone, M. PY - 2013 DA - 2013// TI - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study JO - Lancet Oncol. VL - 14 ID - Swain2013 ER - TY - JOUR AU - Schneeweiss, A. AU - Chia, S. AU - Hickish, T. AU - Harvey, V. AU - Eniu, A. AU - Hegg, R. PY - 2013 DA - 2013// TI - Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) JO - Ann Oncol. VL - 24 ID - Schneeweiss2013 ER - TY - JOUR AU - Coates, A. S. AU - Winer, E. P. AU - Goldhirsch, A. AU - Gelber, R. D. AU - Gnant, M. AU - Piccart-Gebhart, M. PY - 2015 DA - 2015// TI - Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 JO - Ann Oncol VL - 26 ID - Coates2015 ER - TY - STD TI - Mayer EL. Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol Educ Book. 2013. p. 9–14. doi:10.1200/EdBook_AM.2013.33.9. ID - ref111 ER - TY - JOUR AU - Mackey, J. R. AU - Martin, M. AU - Pienkowski, T. AU - Rolski, J. AU - Guastalla, J. P. AU - Sami, A. PY - 2013 DA - 2013// TI - TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial JO - Lancet Oncol VL - 14 ID - Mackey2013 ER - TY - JOUR AU - Martin, M. AU - Ruiz, A. AU - Ruiz Borrego, M. AU - Barnadas, A. AU - González, S. AU - Calvo, L. PY - 2013 DA - 2013// TI - Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study JO - J Clin Oncol. VL - 31 ID - Martin2013 ER -